Focused On-demand Library for Ammonium transporter Rh type A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q02094

UPID:

RHAG_HUMAN

Alternative names:

Erythrocyte membrane glycoprotein Rh50; Erythrocyte plasma membrane 50 kDa glycoprotein; Rhesus blood group family type A glycoprotein; Rhesus blood group-associated ammonia channel; Rhesus blood group-associated glycoprotein

Alternative UPACC:

Q02094; B2R8T8; O43514; O43515; Q7L8L3; Q9H454

Background:

The Ammonium transporter Rh type A, also known as Erythrocyte membrane glycoprotein Rh50, plays a pivotal role in the stability and shape of the erythrocyte membrane. This protein is a component of the ankyrin-1 complex and is involved in the transport of ammonium and CO2 across the erythrocyte membrane. Its ability to leak monovalent cations and regulate RHD membrane expression underscores its significance in erythrocyte physiology and the rhesus blood group antigen expression.

Therapeutic significance:

Given its crucial role in erythrocyte membrane stability and ion transport, the Ammonium transporter Rh type A is linked to diseases such as Regulator type Rh-null hemolytic anemia and Overhydrated hereditary stomatocytosis. Understanding the role of this protein could open doors to potential therapeutic strategies for these red blood cell disorders.